The U.S. Food and Drug Administration has approved Astra Zeneca’s blockbuster cancer drug Astragarus complex for use in people with metastatic breast, lung, ovarian and pancreatic cancer.

The approval, which came Friday, brings Astrgarus complex to more than 20 million people worldwide.

It’s the first approved cancer treatment for the drug, a brand-new drug, that is also the first to be approved by the FDA.

AstraZenec’s approval marks the company’s fifth approval in five years.

Its cancer drug, called AstraVax, has been approved in Europe and other countries and has been tested in patients in the U.K., France and Brazil.

Its approval comes on the heels of Astra Vax’s approval in the United Kingdom and a trial of the drug in France.

It is also Astra’s first approved drug for the treatment of non-Hodgkin’s lymphoma.

The company says it has made substantial progress in treating the disease.